Rasid et al. found that COVID-19 ACS patients had significantly higher in-hospital and 30-day mortality with identified elevated creatinine, peak troponin, heart rate, left ventricular systolic dysfunction, and use of ACE inhibitor or ARBs as independent risk factors for 30-day mortality [13]. The gene discussed is ACE; the disease is COVID-19.